Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The sales mix of high-margin businesses increased, and efficiency in business operations and optimization of fixed costs progressed more than expected. In addition, the expansion of revenue opportunities through broader collaboration with SBCメディカルグループ contributed to the results. The company states that the revision reflects progress in transforming its business portfolio and implementing measures to improve its earnings structure, rather than temporary factors.
| Item | Details |
|---|---|
| Net Sales | ¥2,500 million → ¥2,750 million（+10.0%） |
| Operating profit | ¥400 million → ¥560 million（+40.0%） |
| Ordinary income | ¥390 million → ¥550 million（+41.0%） |
| Profit attributable to owners of the parent | ¥250 million → ¥410 million（+64.0%） |
| Net income per share | 68.62 yen → 115.57 yen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Fiscal year ended September 2025: revenue of ¥1,960 million, operating profit of ¥150 million, ordinary profit of ¥152 million, net income attributable to owners of the parent of ¥44 million, and basic earnings per share of ¥12.32 |
| Reason for the revision | The sales mix of high-margin businesses increased, and efficiency in business operations and optimization of fixed costs progressed more than expected. In addition, the expansion of revenue opportunities through broader collaboration with SBCメディカルグループ contributed to the results. The company states that the revision reflects progress in transforming its business portfolio and implementing measures to improve its earnings structure, rather than temporary factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in the sales mix of high-margin businesses, greater efficiency in business operations and optimization of fixed costs, and the expansion of revenue opportunities through broader collaboration with SBCメディカルグループ have progressed more than expected. The company states that the revision reflects progress in transforming its business portfolio and improving its earnings structure, rather than temporary factors.